Defining Immunogenic and Radioimmunogenic Tumors

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Apr 5

PMID 33816320

Citations 22

Authors

Terry R Medler

Tiffany C Blair

Marka R Crittenden

Michael J Gough

Affiliations

Soon will be listed here.

Abstract

In the cancer literature tumors are inconsistently labeled as 'immunogenic', and experimental results are occasionally dismissed since they are only tested in known 'responsive' tumor models. The definition of immunogenicity has moved from its classical definition based on the rejection of secondary tumors to a more nebulous definition based on immune infiltrates and response to immunotherapy interventions. This review discusses the basis behind tumor immunogenicity and the variation between tumor models, then moves to discuss how these principles apply to the response to radiation therapy. In this way we can identify radioimmunogenic tumor models that are particularly responsive to immunotherapy only when combined with radiation, and identify the interventions that can convert unresponsive tumors so that they can also respond to these treatments.

Citing Articles

A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression.

Baird J, Alice A, Saito R, Chai Q, Han M, Ng C Sci Rep. 2024; 14(1):29913.

PMID: 39622844 PMC: 11612208. DOI: 10.1038/s41598-024-80677-8.

Respiratory adverse effects in patients treated with immune checkpoint inhibitors in combination with radiotherapy: a systematic review and meta-analysis.

Ma Z, Hu J, Wu F, Liu N, Su Q Radiat Oncol. 2024; 19(1):134.

PMID: 39354585 PMC: 11445955. DOI: 10.1186/s13014-024-02489-4.

Targeting Hepatic Cancer Stem Cells (CSCs) and Related Drug Resistance by Small Interfering RNA (siRNA).

Jasim S, Omar Dheyauldeen Salahdin , Malathi H, Sharma N, Rab S, Aminov Z Cell Biochem Biophys. 2024; 82(4):3031-3051.

PMID: 39060914 DOI: 10.1007/s12013-024-01423-5.

Targeting conserved TIM3VISTA tumor-associated macrophages overcomes resistance to cancer immunotherapy.

Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano R, Govaerts J, Trotta R Sci Adv. 2024; 10(29):eadm8660.

PMID: 39028818 PMC: 11259173. DOI: 10.1126/sciadv.adm8660.

Fluorescence tracking demonstrates T cell recirculation is transiently impaired by radiation therapy to the tumor.

Kramer G, Blair T, Bambina S, Kaur A, Alice A, Baird J Sci Rep. 2024; 14(1):11909.

PMID: 38789721 PMC: 11126658. DOI: 10.1038/s41598-024-62871-w.

References

Milas L, Mason K, Ariga H, Hunter N, Neal R, Valdecanas D . CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 2004; 64(15):5074-7. DOI: 10.1158/0008-5472.CAN-04-0926. View

Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A . Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2009; 138(4):1429-40. DOI: 10.1053/j.gastro.2009.10.057. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Walz J, Haese A, Scattoni V, Steuber T, Chun F, Briganti A . Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer. 2008; 113(10):2695-703. DOI: 10.1002/cncr.23885. View

Nesseler J, Lee M, Nguyen C, Kalbasi A, Sayre J, Romero T . Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy. Cancers (Basel). 2020; 12(3). PMC: 7140082. DOI: 10.3390/cancers12030714. View

Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View

Zebertavage L, Alice A, Crittenden M, Gough M . Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity. Sci Rep. 2020; 10(1):7376. PMC: 7193601. DOI: 10.1038/s41598-020-64408-3. View

Kumpers C, Jokic M, Haase O, Offermann A, Vogel W, Gratz V . Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Front Med (Lausanne). 2019; 6:27. PMC: 6425878. DOI: 10.3389/fmed.2019.00027. View

10.

Wennerberg E, Spada S, Rudqvist N, Lhuillier C, Gruber S, Chen Q . CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection. Cancer Immunol Res. 2020; 8(4):465-478. PMC: 7125001. DOI: 10.1158/2326-6066.CIR-19-0449. View

11.

Tran E, Robbins P, Rosenberg S . 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017; 18(3):255-262. PMC: 6295671. DOI: 10.1038/ni.3682. View

12.

Curtin J, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K . HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009; 6(1):e10. PMC: 2621261. DOI: 10.1371/journal.pmed.1000010. View

13.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

14.

Ochsenbein A, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H . Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A. 1999; 96(5):2233-8. PMC: 26766. DOI: 10.1073/pnas.96.5.2233. View

15.

Mantovani A, Allavena P, Sica A . Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004; 40(11):1660-7. DOI: 10.1016/j.ejca.2004.03.016. View

16.

Crocenzi T, Cottam B, Newell P, Wolf R, Hansen P, Hammill C . A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer. 2016; 4:45. PMC: 4986363. DOI: 10.1186/s40425-016-0149-6. View

17.

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman D, Xiao N . Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014; 23(12):2965-70. DOI: 10.1158/1055-9965.EPI-14-0654. View

18.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

19.

Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M . Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999; 189(2):371-80. PMC: 2192989. DOI: 10.1084/jem.189.2.371. View

20.

Sancho D, Mourao-Sa D, Joffre O, Schulz O, Rogers N, Pennington D . Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008; 118(6):2098-110. PMC: 2391066. DOI: 10.1172/JCI34584. View